200 related articles for article (PubMed ID: 35786802)
1. Clinical phenotypes of adult atopic dermatitis and related therapies.
Patruno C; Potestio L; Napolitano M
Curr Opin Allergy Clin Immunol; 2022 Aug; 22(4):242-249. PubMed ID: 35786802
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis.
Napolitano M; Fabbrocini G; Scalvenzi M; Nisticò SP; Dastoli S; Patruno C
Dermatitis; 2020; 31(1):81-84. PubMed ID: 31517666
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
4. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany.
Schmitt J; Abraham S; Trautmann F; Stephan V; Fölster-Holst R; Homey B; Bieber T; Novak N; Sticherling M; Augustin M; Kleinheinz A; Elsner P; Weidinger S; Werfel T
J Dtsch Dermatol Ges; 2017 Jan; 15(1):49-59. PubMed ID: 27862987
[TBL] [Abstract][Full Text] [Related]
5. [THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS].
Murakami Y; Sugiyama A; Ideguchi H; Murakami Y; Amimoto Y; Nishie H; Odajima H
Arerugi; 2020; 69(3):213-217. PubMed ID: 32435023
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.
Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M
Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy.
Ferrucci S; Tavecchio S; Berti E; Angileri L
J Dermatolog Treat; 2021 Jun; 32(4):453-454. PubMed ID: 31442084
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab shows slow, steady effectiveness for intractable prurigo in patients with atopic dermatitis.
Takeuchi S; Inoue K; Kuretake K; Kiyomatsu-Oda M; Furue M
J Dermatol; 2021 May; 48(5):638-644. PubMed ID: 33742710
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
[TBL] [Abstract][Full Text] [Related]
13. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.
Pezzolo E; Gambardella A; Guanti M; Bianchelli T; Bertoldi A; Giacchetti A; Donini M; Argenziano G; Naldi L
J Am Acad Dermatol; 2023 Aug; 89(2):430-432. PubMed ID: 37150301
[No Abstract] [Full Text] [Related]
14. Relative efficacy of systemic treatments for atopic dermatitis.
Seger EW; Wechter T; Strowd L; Feldman SR
J Am Acad Dermatol; 2019 Feb; 80(2):411-416.e4. PubMed ID: 30296535
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
Fang HY; Lian CH
J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.
Patruno C; Fabbrocini G; Longo G; Argenziano G; Ferrucci SM; Stingeni L; Peris K; Ortoncelli M; Offidani A; Amoruso GF; Talamonti M; Girolomoni G; Grieco T; Iannone M; Nettis E; Foti C; Rongioletti F; Corazza M; Veneri MD; Napolitano M;
Am J Clin Dermatol; 2021 Jul; 22(4):581-586. PubMed ID: 33725337
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
18. Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD).
de Bruin-Weller M; Pink AE; Ferrucci SM; Patrizi A; Svensson A; Schuttelaar MLA; Tauber M; Ardeleanu M; Jayawardena S; Daoud M
J Dermatolog Treat; 2022 Aug; 33(5):2565-2570. PubMed ID: 35255779
[TBL] [Abstract][Full Text] [Related]
19. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
